Compare TORM plc (TRMD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

TRMD trades at $40.19, up 3.26% today, with a bullish technical outlook from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a Q4 2025 beat but Q1 and Q2 2026 misses, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026. Cash flow improved to a net positive $6M in 2026 from a negative $113.8M in 2025.

The outlook is positive given robust fundamentals and unanimous analyst buy ratings, though risks include spot rate volatility and insider selling. Revenue growth and dividend yield present opportunities, but investors should monitor freight rate trends and execution on future earnings.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.